Anemia is a common condition in patients with chronic kidney disease (CKD), and its treatment is often challenging because of concerns regarding the safety of current agents; nonresponsiveness to agents; lack of consensus regarding treatment targets; controversy regarding balance between a patient-centric approach versus the use of one-size-fits-all algorithms; and suboptimal coordination between members of the healthcare team managing the anemia.
Although erythropoietic stimulating agents (ESAs) replace deficient native erythropoietin (EPO) in patients with CKD, ESAs do not address iron absorption and mobilization defects that frequently occur in patients with CKD that may blunt the effectiveness of ESA therapy. Stabilization of hypoxia-inducible factor (HIF) via prolyl hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs.
In this PeerView Live web broadcast, our panel of experts will offer insight into best practices regarding the treatment of CKD-associated anemia and emphasize that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance will be combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances.
This activity has been designed to meet the educational needs of nephrologists, nephrology nurses, internal medicine physicians, family medicine physicians, and other clinicians involved in the management of chronic kidney disease.
Upon completion of this activity, participants will be able to:
Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD
Identify benefits and limitations associated with current management approaches to anemia in CKD
Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD
Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD
Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs
Providership, Credit, and Support
This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.
Continuing Nursing Education
Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Successful completion of this continuing nursing education activity will be awarded 1.25 contact hour(s).
Chair & Presenter
Jay B. Wish, MD Indiana University Health Indianapolis, Indiana
Chilnille L. Milbrooks, MSN, FNP-C IU Health Physicians Indianapolis, Indiana
Daniel W. Coyne, MD Washington University School of Medicine St. Louis, Missouri
Disclosure and Conflict of Interest Policy
The Medical Learning Institute, Inc. (MLI) requires faculty, planners, staff, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they, and their spouse/life partners, may have as related to the content of this activity. These disclosures will be provided to learners prior to the start of the activity. All identified COI are thoroughly vetted and resolved according to MLI policy. MLI is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from firstname.lastname@example.org. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.